Addressing Barriers to Optimal Care of Patients with MDD and GAD in the Long-Term Care Setting: The Pharmacy Perspective
neuroscienceCME WebcastPremiere Date: Thursday, January 28, 2010
This activity offers CE credit for:Pharmacists (ACPE)
Credit Expiration Date:
Monday, January 28, 2013
|Manju T. Beier, PharmD, FASCP
Geriatric Consultant Resources LLC
Clinical Associate Professor of Pharmacy
University of Michigan
Ann Arbor, MI
|J. Craig Nelson, MD
Leon J. Epstein Professor of Geriatric Psychiatry
Director of Geriatric Psychiatry
University of California, San Francisco
San Francisco, CA
This case-based activity will focus on addressing barriers from a pharmacist perspective to the optimal care of patients with major depressive disorder (MDD) and generalized anxiety disorder (GAD) in the long-term care setting. The presentations will discuss patient, provider, system, and medication barriers in addition to pharmacoeconomic data with a goal of strengthening the role of the pharmacist on the treatment team and providing practical tools for use in the management of older patients with MDD and GAD in the long-term care setting.
To implement strategies to address patient, provider, and system barriers to optimal care, reduce possibility of drug-drug interactions and evaluate the total costs of treatment for elderly patients with MDD and GAD in the long-term care setting.
At the end of this CE activity, participants should be able to:
- Recognize barriers to the optimal care of the older patient with depression and anxiety and develop one strategy to address these barriers in your practice.
- Critically analyze current treatments for MDD and GAD in the older patient and assess both their risk and benefit.
- Initiate dialogue that analyzes the benefits of treatment and total costs in your review of treatment costs for depression and anxiety in the older patients.
Pharmacists and other healthcare professionals interested in MDD and GAD.
Supported by an educational grant from Forest Laboratories, Inc.
This continuing education activity is co-sponsored by The American Society of Consultant Pharmacists and CME Outfitters, LLC.
CPE Credit (Pharmacists):
The American Society of Consultant Pharmacists and CME Outfitters, LLC, are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
Universal Activity Number: 203-999-10-003-H01-P
Activity Type: knowledge-based
To complete the post-test and evaluation, and to receive your statement of continuing pharmacy education after participating in the activity in its entirety, please go to http://education.ascp.com/psychiatric/node/173/takecourse?, ASCP's Online CE Center, and click the title link under the Featured Continuing Education Courses menu. On the following page, click "Enroll in this Course." Either login to your existing CE Center account, or follow the steps to create a free account (you do not have to be a member of ASCP to create an account).
After registering, click on "Take Quiz" from the Course Information menu and complete the online evaluation and examination. If you do not receive a minimum score of 70% or better, you are permitted one (1) retake. You may choose to print your statement of credit immediately or you may access your statement at any time for printing at a later date. If you need assistance during this process, click on the Help Menu on the top of the CE Center page.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Beier has disclosed that she serves on a speaker's bureau and advisory board for Eli Lilly and Company.
Dr. Nelson has disclosed that he receives research/grant support from NIMH and HRSA. He acts as a consultant and serves on the advisory board of Biovail Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Corcept Therapeutics; Covidien; Eli Lilly and Company; Forest Laboratories, Inc.; Medtronic, Inc.; Merck & Co., Inc.; Orexigen Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Sanofi-aventis; Shire Pharmaceuticals; Sierra Neuropharmaceuticals. He also serves on the data safety monitoring boards of Medtronic, Inc.; NIMH; Orexigen Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Lecture Honoraria from Eli Lilly Global; Otsuka Asia; Schering-Plough Japan.
Christina Ansted, MPH, CCMEP (Planning Committee) has no disclosures to report.
Sharon Tordoff, CCMEP (Planning Committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CPE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
The American Society of Consultant Pharmacists, CME Outfitters, LLC, the faculty, and Forest Laboratories, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).